Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common
-
Shares outstanding
-
229M
-
Number of holders
-
128
-
Total 13F shares, excl. options
-
97.8M
-
Shares change
-
-11.6M
-
Total reported value, excl. options
-
$88.4M
-
Value change
-
-$8.83M
-
Put/Call ratio
-
0
-
Number of buys
-
58
-
Number of sells
-
-66
-
Price
-
$0.91
Significant Holders of Lineage Cell Therapeutics, Inc. - Common (LCTX) as of Q2 2025
164 filings reported holding LCTX - Lineage Cell Therapeutics, Inc. - Common as of Q2 2025.
Lineage Cell Therapeutics, Inc. - Common (LCTX) has 128 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 97.8M shares
of 229M outstanding shares and own 42.72% of the company stock.
Largest 10 shareholders include BROADWOOD CAPITAL INC (49.6M shares), VANGUARD GROUP INC (8.48M shares), Defender Capital, LLC. (6.79M shares), RAFFLES ASSOCIATES LP (5.39M shares), COMERICA BANK (4.6M shares), MILLENNIUM MANAGEMENT LLC (2.6M shares), GEODE CAPITAL MANAGEMENT, LLC (2.43M shares), BlackRock, Inc. (2.26M shares), RENAISSANCE TECHNOLOGIES LLC (1.97M shares), and JANE STREET GROUP, LLC (1.51M shares).
This table shows the top 128 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.